eligibility_summary
Eligibility: adults ≥18 with histologically confirmed pancreatic adenocarcinoma limited to pancreas/regional nodes by CT/MRI+EUS, ≤1 prior line (neoadjuvant) with ≥4-week washout, EGD/EUS feasible, normal cardiac/pulmonary, contraception required. Exclude: pregnant/breastfeeding (neg test ≤14 days), other periampullary cancers, unsafe tumor location, HIV/HBV/HCV, serious illness/infection, immunosuppression ≥10 mg prednisone >1 wk, autoimmune disease, spread beyond nodes, active pancreatitis/inflammation, prior gastrojejunostomy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: RGDCRAdCOX2F, a biological oncolytic, conditionally replicative adenovirus delivered by endoscopic ultrasound–guided intratumoral injection. Mechanism of action: engineered with an RGD motif in the fiber knob to retarget viral entry from CAR to αv integrins (e.g., αvβ3/αvβ5) frequently upregulated on pancreatic tumor cells, enhancing infection, tumor-selective replication leads to oncolysis and immunogenic cell death, potentially boosting local anti‑tumor immunity. Targets: pancreatic adenocarcinoma cells expressing αv integrins, tumor cells permissive to virus replication (COX‑2–linked selectivity implied by vector name).